Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lieberman, A. N.
Right arrow Articles by Nelson, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lieberman, A. N.
Right arrow Articles by Nelson, J.
NEUROLOGY 1982;32:1181
© 1982 American Academy of Neurology

Further studies with pergolide in Parkinson disease

Abraham N. Lieberman, M.D., Menek Goldstein, Ph.D., Govindan Gopinathan, M.D., Morton Leibowitz, M.D., Andreas Neophytides, M.D., Russell Walker, M.D., Emil Hiesiger, M.D. and Jeffrey Nelson, M.D.

New York University School of Medicine, New York, NY.

Pergolide was administered to 56 patients with advanced Parkinson disease who were no longer satisfactorily reponding to levodopa. The group included 45 patients with on-off phenomena. Pergolide, when combined with levodopa, resulted in a 44% decrease in disability as assessed in the on period, a 15% decrease in disability as assessed in the off period, and a 148% increase in the number of hours in which patients were on (from 4.6 ± 0.3 hours to 11.4 ± 0.6 hours). All these changes were significant at 1%. Forty-one of the 56 patients (59%) improved when pergolide was added to levodopa. Mean dose of pergolide was 2.5 mg (range, 0.2 to 10.0 mg). Mean duration of the study was 13 months (range, 1 day to 34 months). Maximum improvement occurred within 2 months and began to decline, usually after 6 months. The major adverse effects necessitating discontinuing pergolide were the occurrence of an organic confusional syndrome (six patients), increased dyskinesias (four patients), and cardiovascular abnormalities (three patients). Nine patients discontinued pergolide because of a lack of effect or declining effect.

Address correspondence and reprint requests to Dr. Lieberman, Professor of Neurology, 530 First Avenue, Suite 5A, New York. NY 10016.

This study was sponsored, in part, by a grant from Eli Lilly & Co., Indianapolis, IN.

Accepted for publication April 1, 1982.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1982 by AAN Enterprises, Inc.